Against the backdrop of increasing challenges in access to innovative drugs, the Laos Dabear version of Sotorasib, with its active ingredients highly similar to the originator drug and significantly reduced treatment costs, has become a new beacon of hope for many financially constrained cancer patients.
How much does the Laos Dabear version of Sotorasib cost?
The Laos Dabear version of Sotorasib is available in a specification of 120mg*56 tablets per box, at a price of approximately $151. The actual price may be influenced by various factors and should be confirmed at the point of sale.
Indications, patient selection, and standard dosing of Sotorasib
Sotorasib is a prescription drug indicated for the treatment of adult patients with non-small cell lung cancer, specifically requiring: the tumor has spread to other parts of the body (i.e., locally advanced or metastatic) or cannot be surgically removed; the tumor tissue or plasma specimen has been tested and confirmed to carry an abnormal KRAS G12C gene mutation; and the patient has received at least one prior line of cancer therapy (e.g., chemotherapy, immunotherapy, etc.). Before initiating treatment, the physician must confirm the presence of a KRAS G12C mutation through a reliable genetic test – plasma testing is preferred; if no mutation is detected in the plasma sample, then tumor tissue testing should be performed. The recommended dosing regimen is: 960 mg (equivalent to eight 120 mg tablets) orally once daily, with or without food. Patients should take the medication at the same time each day, swallowing the tablets whole without chewing, crushing, or splitting. If swallowing whole tablets is difficult, the daily dose can be dispersed in 120 mL of room-temperature non-carbonated water (do not use other liquids), allowing the tablets to disintegrate into small pieces (they will not dissolve completely), and the mixture should be consumed immediately or within 2 hours of preparation, followed by rinsing the cup with another 120 mL of water and drinking it to ensure the full dose is taken. If a dose is missed, it should be taken as soon as possible if within 6 hours; if more than 6 hours have passed, skip the missed dose and take the next dose at the usual time the next day – do not double the dose. If vomiting occurs after taking a dose, do not take an additional dose; simply take the next dose as scheduled the next day. Additionally, when taking antacids (e.g., proton pump inhibitors or H2 receptor antagonists), Sotorasib should be taken 4 hours before or 10 hours after the antacid.
Mechanism of action and key clinical trial data for Sotorasib
Sotorasib is a specific covalent inhibitor targeting the KRAS G12C mutant. Its mechanism of action is unique and precise: the drug molecule forms an irreversible covalent bond with the unique cysteine residue in the KRAS G12C mutant protein, locking KRAS in the inactive GDP-bound state, thereby irreversibly inhibiting KRAS activity and blocking downstream oncogenic signaling pathways. Notably, this drug does not affect wild-type KRAS function, thus offering high selectivity and safety. The FDA accelerated approval was primarily based on positive results from the CodeBreaK 100 clinical trial. This study enrolled 124 patients with locally advanced or metastatic KRAS G12C-mutant non-small cell lung cancer who had previously received an immune checkpoint inhibitor and/or platinum-based chemotherapy and experienced disease progression. The study evaluated the efficacy of Sotorasib at a daily dose of 960 mg. Results showed that the objective response rate (ORR) assessed by an independent review committee was 36% (95% confidence interval: 28-45), meaning more than one-third of patients experienced significant tumor shrinkage; the disease control rate (DCR) was as high as 81% (95% confidence interval: 73-87), indicating that most patients' disease was effectively controlled; the median duration of response (DoR) was 10 months, suggesting that once a response is achieved, it can be sustained for a considerable period. These data strongly confirm the potent anti-tumor activity of Sotorasib in heavily pretreated patients with KRAS G12C-mutant non-small cell lung cancer.
